Precigen (PGEN) Common Equity (2012 - 2026)
Precigen (PGEN) posted quarterly Common Equity of $20.2 million for Q1 2026, up 243.92% year-over-year from $5.9 million in Q1 2025, and down 51.67% quarter-over-quarter from $41.9 million in Q3 2025.
Precigen (PGEN) Common Equity (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Common Equity for 15 consecutive years, with $20.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 243.92% year-over-year to $20.2 million; the TTM figure through Mar 2026 stood at $20.2 million (up 243.92% YoY), while the FY2024 annual figure was $38.5 million, down 67.5% from the prior year.
- Common Equity slipped to $20.2 million in Q1 2026 per PGEN's latest filing, from $41.9 million in the prior quarter.
- Across five years, Common Equity topped out at $184.1 million in Q1 2023 and bottomed at -$36.8 million in Q2 2025.
- Historically, Common Equity has averaged $78.8 million across 5 years, with a median of $64.7 million in 2022.
- Annual changes were most pronounced in 2025 — Common Equity plunged 185.2% — and 2026, when it soared 243.92%.
- Precigen's Common Equity stood at $126.3 million in 2022, then declined by 6.15% to $118.5 million in 2023, then plunged by 67.5% to $38.5 million in 2024, then rose by 8.71% to $41.9 million in 2025, then plunged by 51.67% to $20.2 million in 2026.
- Business Quant data shows PGEN's Common Equity at $20.2 million in Q1 2026, $41.9 million in Q3 2025, and -$36.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | 43.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.58 Mn |
| Mar 31, 2026 | 20.24 Mn |
| Sep 30, 2025 | 41.87 Mn |
| Jun 30, 2025 | -36.78 Mn |
| Mar 31, 2025 | -14.06 Mn |
| Dec 31, 2024 | 38.51 Mn |
| Sep 30, 2024 | 55.38 Mn |
| Jun 30, 2024 | 43.17 Mn |
| Mar 31, 2024 | 97.02 Mn |
| Dec 31, 2023 | 118.50 Mn |
| Sep 30, 2023 | 147.68 Mn |
| Jun 30, 2023 | 166.21 Mn |
| Mar 31, 2023 | 184.13 Mn |
| Dec 31, 2022 | 126.26 Mn |
| Sep 30, 2022 | 142.53 Mn |
| Jun 30, 2022 | 55.65 Mn |
| Mar 31, 2022 | 73.84 Mn |
| Dec 31, 2021 | 107.35 Mn |
| Sep 30, 2021 | 131.25 Mn |
| Jun 30, 2021 | 159.20 Mn |